AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31230798 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-foam dressing (Mepilex® Ag)
Number of subjects: 58
Study 31230798 — intervention group
Group type: COMPARATOR
Intervention: Porcine xenograft dressing (EZderm®)
Number of subjects: 58
Study 29367198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (30 minute session)
Number of subjects: 441
Study 29367198 — intervention group
Group type: COMPARATOR
Intervention: Information booklet (control)
Number of subjects: 441
Study 26797227 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT) group treatment program
Number of subjects: 44
Study 26797227 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study 24888199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 100
Study 24888199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 100
Study 24888199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 100
Study 24888199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (all doses)
Number of subjects: 100
Study 24888199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (higher doses)
Number of subjects: 100
Study 24888199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 100
Study 23259716 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group
Number of subjects: 239
Study 23259716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training group
Number of subjects: 239
Study 23259716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength + endurance training group
Number of subjects: 239
Study 23259716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity recommendations group
Number of subjects: 239
Study 23259716 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (combined)
Number of subjects: 239
Study 21186930 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 ml/kg energy drink
Number of subjects: 80
Study 21186930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml/kg energy drink
Number of subjects: 80
Study 21186930 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.4 ml/kg energy drink
Number of subjects: 80
Study 21186930 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 80
Study 21186930 — intervention group
Group type: COMPARATOR
Intervention: No drink
Number of subjects: 80
Study 17592240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT) 4 mg
Number of subjects: 25
Study 17592240 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (natural course)
Number of subjects: 25
Study 16300417 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 12379552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol combination (FSC)
Number of subjects: 691
Study 10080557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate injections every 2 weeks
Number of subjects: 50
Study 10080557 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate injections every 6 weeks
Number of subjects: 50
Study 7546872 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours' strict bed rest
Number of subjects: 42
Study 7546872 — intervention group
Group type: COMPARATOR
Intervention: Control group (encouraged to remain mobile)
Number of subjects: 42
Study 2284579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic material (Sorbact; n = 1,213)
Number of subjects: 2441
Study 2284579 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% ethanol (n = 1,228)
Number of subjects: 2441
Study 2284579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic material (Sorbact)
Number of subjects: 2441
Study 2284579 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% ethanol
Number of subjects: 2441
Study 7104425 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly deviant stimuli (one lower and one higher in pitch)
Number of subjects: 0
Study 7104425 — intervention group
Group type: COMPARATOR
Intervention: Standard stimuli
Number of subjects: 0
Study 7104425 — intervention group
Group type: EXPERIMENTAL
Intervention: Widely deviant auditory stimulus
Number of subjects: 0
Study 7104425 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant stimuli (both types)
Number of subjects: 0
Study 7104425 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogeneous brain waves
Number of subjects: 0
Study 28504857 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic niche resection
Number of subjects: 103
Study 28504857 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 103
Study 27197855 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (25 g)
Number of subjects: 21
Study 27197855 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (10 g) + glucose (15 g)
Number of subjects: 21
Study 24526291 — intervention group
Group type: EXPERIMENTAL
Intervention: emWave intervention (4-8 sessions)
Number of subjects: 27
Study 24526291 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 27
Study 23584716 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE! weight management program (6 months, includes individual and group sessions)
Number of subjects: 109
Study 23584716 — intervention group
Group type: COMPARATOR
Intervention: Control condition (basic information about diet and exercise every month)
Number of subjects: 109
Study 20501735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 96
Study 20501735 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 96
Study 18426828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in DTC patients
Number of subjects: 34
Study 18426828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in benign FNA cytology
Number of subjects: 34
Study 18426828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in non-informative cytology
Number of subjects: 34
Study 18426828 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in negative controls
Number of subjects: 34
Study 18426828 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in positive controls
Number of subjects: 34
Study 16652071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (peak dose of 2,400 mg/d over 20 weeks)
Number of subjects: 39
Study 16652071 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1,800 and 2,400 mg/day)
Number of subjects: 39
Study 12795579 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced content telephone counseling tailored to the stage of cessation (motivation, self-efficacy, negative mood)
Number of subjects: 0
Study 12795579 — intervention group
Group type: COMPARATOR
Intervention: Basic content telephone counseling primarily consisting of support
Number of subjects: 0
Study 10831474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 531
Study 10831474 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 531
Study 10831474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset major depressive disorder
Number of subjects: 531
Study 10831474 — intervention group
Group type: COMPARATOR
Intervention: Late-onset major depressive disorder
Number of subjects: 531
Study 10831474 — intervention group
Group type: COMPARATOR
Intervention: Never-occurring major depressive disorder
Number of subjects: 531
Study 9336134 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Number of subjects: 445
Study 9336134 — intervention group
Group type: COMPARATOR
Intervention: Accelerated Fractionation (AF) of 30 Gy in 10 daily fractions
Number of subjects: 445
Study 9336134 — intervention group
Group type: COMPARATOR
Intervention: RPA class I patients (KPS of 70 or more, controlled primary tumor, <65 years of age, brain metastases only) in AF arm
Number of subjects: 445
Study 9336134 — intervention group
Group type: EXPERIMENTAL
Intervention: RPA class I patients (KPS of 70 or more, controlled primary tumor, <65 years of age, brain metastases only) in AH arm
Number of subjects: 445
Study 1540455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter data and alarms available (group I)
Number of subjects: 200
Study 1540455 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximeter data and alarms unavailable (group II)
Number of subjects: 200
Study 3887172 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean dose: 57.8 mg per day, max 75 mg per day)
Number of subjects: 12
Study 3887172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30024193 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' affiliative tendencies and time elapsed in therapy
Number of subjects: 109
Study 30024193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bond aspect of the therapeutic alliance
Number of subjects: 109
Study 27670567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel prep group
Number of subjects: 32
Study 27670567 — intervention group
Group type: COMPARATOR
Intervention: No bowel prep group
Number of subjects: 32
Study 25395314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (6 × 3-weekly cycles FE₁₀₀C)
Number of subjects: 44
Study 25395314 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole 2.5 mg, daily for 18-23 weeks)
Number of subjects: 44
Study 25395314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 44
Study 25395314 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 44
Study 24330675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspeptic patients (PADYQ score ≥ 6)
Number of subjects: 50
Study 24330675 — intervention group
Group type: COMPARATOR
Intervention: Non-dyspeptic patients (PADYQ score < 6)
Number of subjects: 50
Study 20146793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Nordic walking twice a week for eight weeks
Number of subjects: 151
Study 20146793 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking with one-hour instruction followed by home advice for eight weeks
Number of subjects: 151
Study 20146793 — intervention group
Group type: COMPARATOR
Intervention: Advice to remain active
Number of subjects: 151
Study 20146793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Nordic walking
Number of subjects: 151
Study 20146793 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking
Number of subjects: 151
Study 17459096 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day (F group)
Number of subjects: 89
Study 17459096 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily (O group)
Number of subjects: 89
Study 17459096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of orlistat and fenofibrate (OF group)
Number of subjects: 89
Study 16189259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid), 500 mg/d orally for 7 days
Number of subjects: 200
Study 16189259 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I therapy after Telepaque
Number of subjects: 200
Study 16189259 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole, 30-40 mg daily until euthyroid followed by 131I
Number of subjects: 200
Study 16189259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid)
Number of subjects: 200
Study 16189259 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole
Number of subjects: 200
Study 16189259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 16189259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after mean follow-up of 11 years
Number of subjects: 200
Study 12499994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-fortified infant formula (NF)
Number of subjects: 336
Study 12499994 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 336
Study 10376390 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 micrograms/day
Number of subjects: 227
Study 10376390 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone MDI 800 micrograms/day
Number of subjects: 227
Study 8885674 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (1st dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (2nd dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (3rd dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1st dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2nd dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3rd dose)
Number of subjects: 0
Study 8885674 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (local reactions)
Number of subjects: 0
Study 8885674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (local reactions)
Number of subjects: 0
Study 8885674 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (systemic side effects)
Number of subjects: 0
Study 8885674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (systemic side effects)
Number of subjects: 0
Study 2065925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg.kg‐1.day‐1 for 1 month)
Number of subjects: 20
Study 2065925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (15 mg.kg‐1.day‐1 for 1 month)
Number of subjects: 20
Study 2065925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (during weight-reduction period)
Number of subjects: 20
Study 2065925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (during weight-reduction period)
Number of subjects: 20
Study 6587751 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (Isoptin) 120 mg X 3 for four weeks
Number of subjects: 20
Study 6587751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31522334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 46
Study 31522334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 46
Study 31522334 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and Pimecrolimus (combined analysis)
Number of subjects: 46
Study 29752248 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle intervention for hypertensive patients
Number of subjects: 264
Study 27236379 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD‐DS with a 200‐cm common channel (study group)
Number of subjects: 72
Study 27236379 — intervention group
Group type: COMPARATOR
Intervention: BPD‐DS with a 100‐cm common channel (control group)
Number of subjects: 72
Study 25121612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) at 10°C for 10 min
Number of subjects: 10
Study 25121612 — intervention group
Group type: COMPARATOR
Intervention: Active recovery (low‐intensity cycling) for 10 min
Number of subjects: 10
Study 22927454 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent dosing schedule of aerosolized ribavirin
Number of subjects: 50
Study 22927454 — intervention group
Group type: COMPARATOR
Intervention: continuous dosing schedule of aerosolized ribavirin
Number of subjects: 50
Study 21548546 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump myocardial revascularization
Number of subjects: 120
Study 21548546 — intervention group
Group type: COMPARATOR
Intervention: Off-pump myocardial revascularization
Number of subjects: 120
Study 16286540 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (30-microg, once weekly, intramuscular)
Number of subjects: 36
Study 14562858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0
Study 10371118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (PVM: 80 mg/m2 Cisplatin on day 1, 2-3 mg/m2 Vindesine on day 1 and/or day 8, 8 mg/m2 Mitomycin C on day 1, followed by 400 mg/day UFT orally for 1 year)
Number of subjects: 225
Study 10371118 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 225
Study 10371118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (PVM)
Number of subjects: 225
Study 8664018 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (WBC)
Number of subjects: 40
Study 8664018 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC)
Number of subjects: 40
Study 2054273 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 27
Study 2054273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetapp (DIM)
Number of subjects: 98
Study 6185020 — intervention group
Group type: COMPARATOR
Intervention: Brompheniramine maleate (BPM)
Number of subjects: 98
Study 6185020 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine hydrochloride (PEH)
Number of subjects: 98
Study 6185020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 98
Study 31630182 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 25
Study 31630182 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25
Study 31630182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 25
Study 31630182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 25
Study 29783900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg PO daily)
Number of subjects: 90
Study 29783900 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg PO daily)
Number of subjects: 90
Study 29783900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28544171 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 153
Study 28544171 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 153
Study 26541070 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 0
Study 26541070 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study 24503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin prescribed according to predicted warfarin dose based on VKORC1 and CYP2C9 genotypes
Number of subjects: 220
Study 24503429 — intervention group
Group type: COMPARATOR
Intervention: Warfarin prescribed according to empirical clinician estimates
Number of subjects: 220
Study 24503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 220
Study 24503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Average predicted dose for stable dose patients
Number of subjects: 220
Study 24503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Average effective dose for stable dose patients
Number of subjects: 220
Study 24503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between average predicted dose and actual dose
Number of subjects: 220
Study 21411056 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning led by fourth‐year medical students
Number of subjects: 60
Study 21411056 — intervention group
Group type: COMPARATOR
Intervention: Resident-assisted learning led by obstetrics and gynecology residents
Number of subjects: 60
Study 18791585 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand
Number of subjects: 40
Study 18791585 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 40
Study 16386259 — intervention group
Group type: EXPERIMENTAL
Intervention: STAEST spread (1.93-1.98g/day) for 10 weeks
Number of subjects: 39
Study 16386259 — intervention group
Group type: EXPERIMENTAL
Intervention: STEEST spread (1.93-1.98g/day) for 10 weeks
Number of subjects: 39
Study 16386259 — intervention group
Group type: COMPARATOR
Intervention: Control group (spread without sterols or stanols for 20 weeks)
Number of subjects: 39
Study 16191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (acetylcholinesterase inhibitor), dosage and duration not specified
Number of subjects: 1219
Study 16191240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study 10969126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes (VT group)
Number of subjects: 187
Study 10969126 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (WW group)
Number of subjects: 187
Study 10969126 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive language improvement
Number of subjects: 187
Study 10969126 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive language development
Number of subjects: 187
Study 8853805 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption therapy utilizing Prosorba column
Number of subjects: 0
Study 8853805 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption therapy
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Timoptic (timolol maleate)
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagan (levobunolol hydrochloride)
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Betoptic (betaxolol hydrochloride)
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilopine Gel (pilocarpine hydrochloride)
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Miostat (carbachol)
Number of subjects: 0
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopidine (apraclonidine hydrochloride)
Number of subjects: 0